Company Information

  

Address: C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17 
City: RAMSEY 
State: NJ 
Zip Code: 07446 
Telephone: (201) 478-5552 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

Unless the context otherwise requires, references in this Business section to "ADMA," "ADMA Biologics," the "Company," "we," "us" and "our" refer to ADMA Biologics, Inc., a Delaware corporation, as well as its subsidiary, ADMA Plasma Biologics, Inc., a Delaware corporation, including its wholly-owned subsidiary, ADMA Bio Centers Georgia Inc., or ADMA BioCenters, a Delaware corporation, taken as a whole. Business of ADMA Overview ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.74NAN/E
03/2017-1.69NAN/E
12/2016-1.61NAN/E
03/2016-1.79NAN/E
12/2015-1.73NAN/E
09/2015-1.66NAN/E
06/2015-1.56NAN/E
03/2015-1.54NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.19Total Liab/Total Assets1.19
Net Inc/Total Assets-0.82Total Liab/Inv Cap4.44
Net Inc/Inv Cap-3.08Total Liab/Comm Equity0.27
Pretax Inc/Net Sales-1.83Interest Coverage Ratio-7.71
Net Inc/Net Sales-1.83Curr Debt/Equity-1.37
Cash Flow/Net Sales-1.71LTD/Equity-2.77
SG&A/NetSales1.31Total Debt/Equity-4.14
Asset Utilization   Liquidity  
Net Receivables Turnover10.98Quick Ratio1.48
Inventory Turnover1.50Current Ratio1.93
Inventory Day Sales0.00Net Rec/Curr Assets0.05
Net Sales/Work Cap1.02Inv/Curr Assets0.23
Net Sales/PP&E5.33  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 3.40 2.63 3.33 2.94
Cost of Goods Sold 4.33 1.62 2.01 1.74
Selling & Admin Exps 6.04 5.76 4.67 3.26
Operating Income -8.40 -5.94 -3.94 -3.74
Interest Exp 0.64 0.62 0.63 0.61
Pretax Income -9.04 -6.54 -4.56 -4.33
Other Income 0.01 0.02 0.01 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -9.04 -6.54 -4.56 -4.33

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 25.57 8.79 15.31 18.93
Receivables - Total 2.29 0.84 1.02 1.33
Inventories - Total 13.15 5.31 5.02 4.62
Total Current Assets 44.27 15.68 21.66 25.36
Net Property, Plant & Equipment 28.63 1.88 2.00 2.11
Total Assets 84.64 17.59 23.69 27.50
Liabilities        
Accounts Payable 8.82 6.13 4.95 4.60
Debt in Current Liabilities 6.67 6.68 6.13 4.46
Total Current Liabilities 15.65 12.96 11.22 9.21
Long-Term Debt 21.98 10.86 12.34 13.82
Total Liabilities 56.96 28.35 28.14 27.65
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 NA NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -122.51 -113.47 -106.93 -102.38
Treasury Stock NA NA NA NA
Total Stockholders' Equity 27.68 -10.76 -4.46 -0.15
Total Liabilities and Stockholders' Equity 84.64 17.59 23.69 27.50

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -8.78 -5.40 -3.61 -4.68
Net Cash Provided by Investing Activities 12.65 5.14 5.63 0.24
Net Cash Provided by Financing Activities 13.15 -1.12 -0.00 -0.20

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20121.12-7.30--
12/20133.07-15.53-2.38
12/20145.92-16.81-1.81
12/20157.18-17.97-1.73
12/201610.66-19.52-1.61
Growth Rates75.72----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17218,91151.80




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.